Company: LENZ
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001815776-25-000071
Chunk: 266

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part II, Item 1A
Chunk 266
---
 adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

There were no sales of unregistered securities by us during the quarter ended September 30, 2025 that were not previously reported in current reports on Form 8-K filed with the SEC.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

80

Not applicable.

Item 5. Other Information

Securities Trading Plans of Directors and Executive Officers

On August 11, 2025, Evert Schimmelpennink, Chief Executive Officer of the Company, entered into a 10b5-1 trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. This 10b5-1 trading plan provides for the sale of 225,000 shares of the Company’s common stock related to the exercise of option awards granted to Mr. Schimmelpennink. This 10b5-1 trading plan will become effective on January 19, 2026 and will terminate on June 30, 2026, subject to earlier termination as provided in the plan.

On August 12, 2025, Shawn Olsson, Chief Commercial Officer of the Company, entered into a 10b5-1 trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. This 10b5-1 trading plan provides for the sale of 66,891 shares of the Company’s common stock related to the exercise of option awards granted to Mr. Olsson. This 10b5-1 trading plan will become effective on November 17, 2025 and will terminate on October 19, 2026, subject to earlier termination as provided in the plan.

During our last fiscal quarter, none of our other directors or officers, as defined in Rule 16a-1(f